Monday afternoon I popped on to BNN Bloomberg to have my regular chat with Catherine Murray. These are always fun because we focus on what actually happening in the market, versus all the gossip that revolves around it.

Remember, we're coming off my Just Buy Them Baby interview with Catherine from July. We got a lot of funny emails from people after that one. But as it turns out, just buying them worked out very well.

So where do we go from here?

Here's the interview in full: 

Emerging Markets remain in focus and today we're identifying why its trend relative to Developed Markets is likely to accelerate higher.

This is a follow-up to our last few Emerging-Market-focused posts --- August 12th, September 11th, and September 25th.

From the desk of Steve Strazza @Sstrazza and Louis Sykes @haumicharts

At the beginning of each week, we publish performance tables for a variety of different asset classes and categories along with commentary on each.

Looking at the past helps put the future into context. In this post, we review the relative strength trends at play and preview some of the things we’re watching in order to profit in the weeks and months ahead.

In last week's report, we outlined how the market was in an incredibly healthy state of order. We've been seeing rotation into SMIDS and Micro-Caps, strong breadth, and a sustained bid for Growth, particularly down the market-cap scale.

This week, we're harping on a similar theme.

The weight of the evidence, particularly from an intermediate and long-term time horizon, looks excellent.

But from a more short-term and tactical perspective, it would be healthy for many indexes down the market-cap scale to digest their gains. Many sector indexes and ratios are...

One thing you'll read between the lines in nearly everything we do here at All Star Options and allstarcharts.com: We stick with winners. We ride trends. We get long relative strength and we get short relative weakness. We don't overcomplicate things. We don't need to be the Hero who shorts a parabolic stock at its zenith, or buys the oversold stock at its generational bottom. Those trades make for sexy stories, but that graveyard is a mile wide and 50 feet deep.

With this in mind, here's an undeniable leader that is setting up again:

From the desk of Steve Strazza @Sstrazza.

Welcome to our “Under The Hood” column for the week ending December 04, 2020.

What we do is analyze the most popular stocks during the week and find opportunities to either join in and ride these momentum names higher, or fade the crowd and bet against them.

We use a variety of sources to generate the list of most popular names. There are so many new data sources available that all we need to do is organize and curate them in a way that shows us exactly what we want: A list of stocks that are seeing an unusual increase in investor interest.

Whether we’re measuring increasing interest based on large institutional purchases, unusual options activity, or simply our proprietary lists of trending tickers… there is a lot of overlap.

The bottom line is there are a million ways to skin this cat. Relying on our entire arsenal of data makes us confident that we’re producing the best list each week and gives us more optionality in terms of finding the most favorable trade setups for our clients.

As the market continues to grind higher, we continue to find plenty of new...

This week we're looking at a long setup in the Pharma sector.

We retired our "Five Bull Market Barometers" in mid-July to make room for a new weekly post that's focused on the three most important charts for the week ahead.

This is that post, so let's jump into this week's edition.

When I was younger I would fight trends a lot. I was that guy regularly betting on mean reversions.

Then over time I realized just how stupid that was.

I was actually a permabear in early 2013. I admit it. It was a great lesson that will help me for the rest of my investing life.

We all have to learn somehow.

But that's the point. We need to learn eventually.

All Star Charts is known for its Top-Down analysis. In this process, we begin at the asset-class level to ascertain the best category of investment that matches our reward/risk ratio. This then trickles down to specific instruments of investment on the basis of relative strength and momentum.

Let’s take a look at this procedure in our weekly column, The Top/Down Take, and help you understand our analysis better.

Last time it was Tata Consultancy Services (TCS), but today the stock we're looking at is IndusInd Bank (INDUSINDBK) which has been tearing through the roof since November.

Are you wondering whether it's justifiable for stocks to be doing what they're doing?

We continue to make new all-time highs, which makes perfect sense. More stocks are participating to the upside. More sectors and industry groups are catching a bid. And more countries around the world are breaking out.

And the bond market agrees!

This has never been about a virus or a vaccine. It's been about credit spreads, which are hitting their lowest levels since February.

If stocks were going to fall apart and these permabears were going to be right, for once, then we'd see it in credit.

We're not.

In fact, it's actually the exact opposite:

Last year Sean and I flew out to Tokyo looking for Japanese Candlesticks.

Here's what we found....

As Steve Strazza was putting together the latest "2-to-100" report, he and I were chatting about his latest great stock idea. He is pretty excited about this one, and who am I to not join him?

Let's get right to it.